Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research report sent to investors on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

RVNC has been the topic of several other research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Barclays reduced their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Finally, Mizuho dropped their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a report on Tuesday, December 10th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Up 0.5 %

Shares of RVNC opened at $3.67 on Tuesday. The company has a 50-day moving average price of $3.44 and a two-hundred day moving average price of $4.57. The stock has a market cap of $383.11 million, a price-to-earnings ratio of -1.90 and a beta of 0.86. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.56.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. Equities research analysts expect that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

Large investors have recently made changes to their positions in the company. Inspire Investing LLC raised its holdings in Revance Therapeutics by 69.0% during the 4th quarter. Inspire Investing LLC now owns 131,892 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 53,837 shares during the last quarter. FNY Investment Advisers LLC raised its stake in shares of Revance Therapeutics by 160.4% during the fourth quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock worth $1,452,000 after buying an additional 294,323 shares during the last quarter. Exome Asset Management LLC acquired a new position in Revance Therapeutics in the third quarter valued at approximately $1,804,000. Oddo BHF Asset Management Sas bought a new position in Revance Therapeutics in the third quarter valued at approximately $3,763,000. Finally, Virtu Financial LLC acquired a new stake in Revance Therapeutics during the 3rd quarter worth $120,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.